BGM Stock Overview
Manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BGM Group Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.04 |
| 52 Week High | US$8.96 |
| 52 Week Low | US$1.78 |
| Beta | 1.46 |
| 11 Month Change | -11.78% |
| 3 Month Change | 28.00% |
| 1 Year Change | 217.62% |
| 33 Year Change | -54.80% |
| 5 Year Change | n/a |
| Change since IPO | -85.92% |
Recent News & Updates
Qilian International Holding Group Limited (NASDAQ:BGM) Surges 29% Yet Its Low P/S Is No Reason For Excitement
Sep 17
Qilian International Holding Group Limited's (NASDAQ:QLI) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Jun 22The Market Doesn't Like What It Sees From Qilian International Holding Group Limited's (NASDAQ:QLI) Revenues Yet
May 02Recent updates
Qilian International Holding Group Limited (NASDAQ:BGM) Surges 29% Yet Its Low P/S Is No Reason For Excitement
Sep 17Qilian International Holding Group Limited's (NASDAQ:QLI) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Jun 22The Market Doesn't Like What It Sees From Qilian International Holding Group Limited's (NASDAQ:QLI) Revenues Yet
May 02Earnings Not Telling The Story For Qilian International Holding Group Limited (NASDAQ:QLI) After Shares Rise 79%
Dec 31Qilian International Non-GAAP EPS of $0.01, revenue of $32.09M
Oct 03We Think You Can Look Beyond Qilian International Holding Group's (NASDAQ:QLI) Lackluster Earnings
Sep 23Qilian International signs Gan Di Xin's exclusive distribution agreement
May 05Qilian International Holding Group Limited's (NASDAQ:QLI) Share Price Matching Investor Opinion
Apr 12Shareholder Returns
| BGM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.2% | 2.8% | 2.2% |
| 1Y | 217.6% | 11.8% | 32.6% |
Return vs Industry: BGM exceeded the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: BGM exceeded the US Market which returned 31.6% over the past year.
Price Volatility
| BGM volatility | |
|---|---|
| BGM Average Weekly Movement | 11.2% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BGM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BGM's weekly volatility has decreased from 20% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 298 | Chen Xin | www.bgm.ltd |
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications.
BGM Group Ltd Fundamentals Summary
| BGM fundamental statistics | |
|---|---|
| Market cap | US$50.05m |
| Earnings (TTM) | -US$7.86m |
| Revenue (TTM) | US$29.87m |
1.7x
P/S Ratio-6.4x
P/E RatioIs BGM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGM income statement (TTM) | |
|---|---|
| Revenue | US$29.87m |
| Cost of Revenue | US$29.00m |
| Gross Profit | US$870.77k |
| Other Expenses | US$8.73m |
| Earnings | -US$7.86m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.10 |
| Gross Margin | 2.92% |
| Net Profit Margin | -26.32% |
| Debt/Equity Ratio | 0% |
How did BGM perform over the long term?
See historical performance and comparison